The recent disclosure of the results from the SWOG Pancreatic trial-in which Erby failed to meet survival endpoints has been misinterpreted IMHO by the press. This population was "patients with locally advanced unresectable or metastatic pancreatic cancer"
It will be extremely interesting to see the results of the following studdy, in which patients that had successful resections were used: Even though it was a phase II, I believe that some results are already in.
"Phase II Randomized Study of Adjuvant Therapy Comprising Bevacizumab Versus Cetuximab in Combination With Gemcitabine Hydrochloride, Capecitabine, and Radiotherapy in Patients With Completely Resected Carcinoma of the Pancreas"
NCI
ECOG-E2204
NCT00305877, CALGB-ECOG-E2204, NCCTG-ECOG-E2204, SWOG-ECOG-E2204
This was a "faceoff" of ERBY vs. Avastin - both arms having Gen. and radiation.
News 
Market Data 
Discover 
